Search

Axsome Therapeutics Inc

Open

SectorGezondheidszorg

204.51 -1.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

205

Max

207.95

Belangrijke statistieken

By Trading Economics

Inkomsten

13M

-51M

Verkoop

27M

218M

EPS

-0.99

Winstmarge

-23.498

Werknemers

1,346

EBITDA

11M

-50M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+40.06% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

468M

11B

Vorige openingsprijs

205.66

Vorige sluitingsprijs

204.51

Nieuwssentiment

By Acuity

34%

66%

95 / 340 Rangschikking in Healthcare

Axsome Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2026, 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20 aug 2026, 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17 aug 2026, 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14 aug 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13 aug 2026, 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12 aug 2026, 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11 aug 2026, 19:45 UTC

Social Media
News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10 aug 2026, 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7 aug 2026, 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6 aug 2026, 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5 aug 2026, 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

4 aug 2026, 23:36 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing sentiment amid record highs in stock markets.

3 aug 2026, 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31 jul 2026, 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30 jul 2026, 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29 jul 2026, 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28 jul 2026, 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27 jul 2026, 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

24 jul 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

22 jul 2026, 19:11 UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

21 jul 2026, 19:51 UTC

Social Media
News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

20 jul 2026, 21:21 UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Peer Vergelijking

Prijswijziging

Axsome Therapeutics Inc Prognose

Koersdoel

By TipRanks

40.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 291 USD  40.06%

Hoogste 380 USD

Laagste 251 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Axsome Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Sentiment

By Acuity

95 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat